Neurogene (STU:UU8) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UU8 Neurogene Inc STU:UU8
20 GF Score
Price €34.80
! 4 Warning Signs
View Full Analysis

What is Neurogene FFO?

FFO (Funds from operations) only applies to REITs.

STU:UU8
20GF Score
Neurogene Inc STU:UU8
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Business Description

Other Exchanges NGNE:USA
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
20GF Score

Get the complete analysis for STU:UU8

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.80
Price